MVP方案动脉灌注治疗非小细胞肺癌的临床研究  

The clinical research of MVP scheme artery perfusion in treatment of non-small-cell lung cancer

作　　者：曹强 荣阳[2] 

机构地区：[1]辽宁省辽阳市第三人民医院放射介入科,辽宁辽阳111000 [2]中国医科大学辽阳中心医院放射科,辽宁辽阳111000

出　　处：《中国现代医生》2012年第3期148-149,151,共3页China Modern Doctor

摘　　要：目的观察MVP方案动脉灌注治疗非小细胞肺癌(NSCLC)的临床疗效。方法选择2007年1月～2010年12月收治的经病理证实的NSCLC患者100例采用MVP方案[丝裂霉素(MMC)+长春地辛(VDS)+顺铂(DDP)]、支气管动脉灌注(BAI)治疗,BAI治疗每例至少2次。结果本组总有效率84%,总体生存期13个月,中位生存期平均16个月,一年生存率78%。多数患者治疗后疼痛减轻、肿块缩小、通气改善、血痰消失或减少、肺不张复张。多、中血供型肺癌明显高于少血供型肺癌(P<0.01)。结论 MVP方案、BAI治疗NSCLC效果确切,值得临床推广应用。Objective To observe the effect of MVP scheme artery perfusion treatment on the non-small-cell lung cancer （NSCLC） curative. Methods All of 100 patients with NSCLC pathologically proved from Jan 2007 to Nov 2010 were given MVP [Mitomycin （MMC） ＋ Vindesine （VDS） ＋ Cisplatin （DDP）] and the bronchial arterial peffusion （BAI）（each patient at least twice）. Results The total effective rate was 84%, total survival time was 13 months, median survival time was 16 months, and one-year survival rate was 78%. Most patients pain mitigated, mass narrowed, improve ventilation, blood spu- tum disappear or reduce, ventilation improved significantly. In the more blood supply for lung cancer was significantly higher than the less blood supply for lung cancer （P 〈 0.01）. Conclusion MVP plan BAI has a good result in the treatment of NSCLC.

关 键 词：化疗 动脉灌注 非小细胞肺癌 介入 

分 类 号：R734.2[医药卫生—肿瘤]